Work

Poster: IBCL-131: inMIND: A Phase 3 Study of Tafasitamab + Lenalidomide Add-On to Rituximab vs Placebo + Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)

Year: 2021

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(21)01550-0

Authors: Laurie H. Sehn, Christian W. Scholz, Stefano Luminari, Antonio Salar, Björn E. Wahlin, Ajay K. Gopal, Christophe Bonnet, Marek Trneny, Shankara Paneesha, Oliver Manzke, Francis Seguy, Di Li, Kai Hübel

Institutions: University of British Columbia, Vivantes Klinikum, Hospital Del Mar, Municipal Institute for Medical Research, Karolinska Institutet, University of Washington, University of Washington Medical Center, University of Liège, Centre Hospitalier Universitaire de Liège, Charles University, General University Hospital in Prague, University Hospitals Birmingham NHS Foundation Trust, Incyte (United States), University Hospital Cologne

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4200546160

FWCI:

Cites:

Cited by:

Related to: 10